Australia's most trusted
source of pharma news
Posted 12 October 2021 AM
An ugly battle has erupted over AbbVie's blockbuster Humira with the company branded as 'un-Australian' and put on notice for 'perceived anti-competitive' behaviour as it attempts to continue its dominance in the adalimumab market.
The Australian Biosimilars Academy (ABA), headed by former National President of the Pharmacy Guild George Tambassis, has lashed out in a scathing attack on AbbVie, accusing the company of putting profits before patients in its efforts to continue its hold on the adalimumab market, even though the patent for Humira has now expired.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.